Your new post is loading...
Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.
|
Scooped by
BigField GEG Tech
June 1, 2016 1:54 AM
|
Scoop.it!
No comment yet.
Sign up to comment
In this work, the authors highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.